Deborah Waurishuk
Family · Millsboro, DENPI 1821097791
Payments from drug & device makers
Across 101 payments — averaging $31.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$868
- Dexcom, Inc.$249
- Biohaven Pharmaceuticals, Inc.$209
- Boehringer Ingelheim$123
- Novo Nordisk$116
- plus $605 from 12 others
What the payments were for
- Food & beverage$3,179100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $1,010 |
| Amgen | 18 | $868 |
| Dexcom, Inc. | 3 | $249 |
| Biohaven Pharmaceuticals, Inc. | 2 | $209 |
| Boehringer Ingelheim | 9 | $123 |
| Novo Nordisk | 7 | $116 |
| Lilly USA, LLC | 5 | $89 |
| AbbVie | 3 | $89 |
| GSK | 6 | $81 |
| Exact Sciences | 1 | $74 |
| Sunovion Pharmaceuticals Inc. | 3 | $59 |
| Pfizer | 4 | $55 |
| Astellas Pharma US Inc | 3 | $47 |
| Bayer | 2 | $32 |
| Merck | 2 | $31 |
| Dynavax Technologies Corporation | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVENITY$481
- BREZTRI$245
- DEXCOM G7 GSS (161)$129
- Repatha$125
- AIRSUPRA$124
- AIMOVIG$122
- FARXIGA$120
- NURTEC ODT$115
How this compares
$3,179 in reported general payments places this provider in the 85th percentile of 523 family providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 78 | $119,161 |
| FarxigaDapagliflozin Propanediol | 62 | $61,277 |
| JardianceEmpagliflozin | 63 | $53,663 |
| EliquisApixaban | 34 | $34,767 |
| RybelsusSemaglutide | 19 | $32,793 |
| OzempicSemaglutide | 22 | $28,080 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $23,850 |
| TrulicityDulaglutide | 14 | $20,899 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $18,733 |
| XareltoRivaroxaban | 13 | $18,255 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,978 |
| Repatha SureclickEvolocumab | 26 | $13,944 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $11,366 |
| Spiriva HandihalerTiotropium Bromide | 15 | $10,029 |
| Rosuvastatin Calcium | 404 | $6,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $89 | $140,06092 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,010 | $79,25590 claims |
| Novo NordiskRybelsus, Ozempic | $116 | $60,87341 claims |
| Boehringer IngelheimJardiance | $123 | $53,66363 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $81 | $41,62482 claims |
| PfizerEliquis, Paxlovid | $55 | $36,19645 claims |
| AbbVieSynthroid | $89 | $2,29248 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 523 family providers in Delaware.
Other family in Millsboro
- Nicole CaselliMillsboro$5K
- Lisa HohlMillsboro$4K
- Sean ForsythMillsboro$4K
- Mandi LahmanMillsboro$4K
- Brandi GreggeMiddletown$110K
- Tracy EstesWilmington$59K
- Kathy GallagherNewark$53K
- Jodie DelesioNewark$50K
- Abby AllenGeorgetown$43K
- Taylor HodgesLewes$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.